Structure Therapeutics (GPCR) Common Equity (2022 - 2026)

Structure Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 75.48% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 75.48% YoY), while the FY2025 annual figure was $1.5 billion, up 75.34% from the prior year.
• Common Equity was $1.4 billion for Q1 2026 at Structure Therapeutics, down from $1.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.5 billion in Q4 2025 to a low of -$115.1 million in Q4 2022.
• Historically, Common Equity has averaged $538.3 million across 5 years, with a median of $453.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity surged 493.4% in 2023, then retreated 16.17% in 2025.
• A 5-year view of Common Equity shows it stood at -$115.1 million in 2022, then soared by 493.4% to $453.0 million in 2023, then soared by 90.93% to $864.8 million in 2024, then soared by 75.34% to $1.5 billion in 2025, then retreated by 4.57% to $1.4 billion in 2026.
• The last three Common Equity figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $770.0 million (Q3 2025), per Business Quant data.